Filing Flows › Health Care › Lucid Diagnostics (LUCD)
Lucid Diagnostics (LUCD) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Lucid Diagnostics (LUCD) Q2 2026 earnings results →
Q2 2026 Revenue up 27% year over year to $1.5M · 793¢ of every $1 of revenue lost · operating margin -868.5%
Lucid Diagnostics made $1.5M in Q2 2026 (+27% Y/Y). Operating margin -868.5%, net loss $11.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.5M in Q2 2026, up 27% year over year and up 17% from the previous quarter.
Operating costs exceeded revenue by $12.8M, an operating margin of -868.5%. Total costs grew 14% against revenue growth of 27%. The fastest-growing cost line was Sales & marketing (+44%). The quarter ended with a net loss of $11.7M, narrower than the previous quarter's $13.9M loss.
Operating cash flow was −$11.3M. Non-cash charges added back $224K of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items used $1.5M. Capital expenditures of $21K exceeded it, leaving free cash flow of −$11.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $1.5M | +27% | -868.5% | −$11.7M | −$11.3M |
| Q1 2026 | 10-Q | May 13, 2026 | $1.3M | +52% | -964.5% | −$13.9M | −$12.1M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $1.2M | +3% | -971.0% | −$10.4M | −$10.9M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $1.2M | +19% | -978.8% | −$4.4M | −$10.5M |
| Q1 2025 | 10-Q | May 13, 2025 | $828K | -17% | n/m | −$26.9M | −$12.5M |
| Q4 2024 | 10-K | Mar 24, 2025 | $1.2M | +15% | n/m | −$11.5M | −$9.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Lucid Diagnostics
Unless the context otherwise requires, “ we ” , “ us ” , and “ our ” , the “ Company ” , “ Lucid ” and “ Lucid Diagnostics ” refer to Lucid Diagnostics Inc. and its subsidiaries LucidDx Labs Inc. ( “ LucidDx Labs ” ) and CapNostics, LLC ( “ CapNostics ” ). Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics technology company. Lucid is focused on the millions of patients with gastroesophageal reflux disease (“GERD”), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (“EAC”).
In its own words, from its 10-K, filed Mar 25, 2026.
Lucid Diagnostics against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +27% against the peers' median +5%. Operating margin: -868.5% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| LUCD Lucid Diagnostics | Q2 2026 | $1.5M | +27% | -868.5% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Lucid Diagnostics 10-Q on SEC EDGAR · CIK 1799011 · Surgical & Medical Instruments & Apparatus
13F: who owns LUCD and who is buying
More on LUCD
History
Every quarter: Q2 2026 results · Q1 2026 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results